Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry

Maria E. Zannin, Carolina Birolo, Valeria M. Gerloni, Elisabetta Miserocchi, Irene Pontikaki, Maria P. Paroli, Claudia Bracaglia, Alison Shardlow, Fulvio Parentin, Rolando Cimaz, Gabriele Simonini, Fernanda Falcini, Fabrizia Corona, Stefania Viola, Riccardo De Marco, Luciana Breda, Francesco La Torre, Fabio Vittadello, Giorgia Martini, Francesco Zulian

Research output: Contribution to journalArticle

Abstract

Objective. To evaluate safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of juvenile idiopathic arthritis-related anterior uveitis (JIA-AU). Methods. Starting January 2007, patients with JIA-AU treated with IFX and ADA were managed by a standard protocol and data were entered into the National Italian Registry (NIR). At baseline, all patients were refractory to standard immunosuppressive treatment and/or were corticosteroid-dependent. Data recorded every 3 months included uveitis course, number/type of ocular complications, drug-related adverse events (AE), treatment change or withdrawal, and laboratory measures. Data of patients treated for at least 1 year were retrieved from the NIR and analyzed using descriptive statistics. Treatment efficacy was based on change in uveitis course and in number of ocular complications. Results. Up to December 2009, data for 108 patients with JIA-AU treated with anti-tumor necrosis factor-α agents were recorded in the NIR and data from 91, with at least 12 months' followup, were included in the study. Forty-eight patients were treated with IFX, 43 with ADA. Forty-seven patients (55.3%) achieved remission of AU, 28 (32.9%) had recurrent AU, and 10 (11.8%) maintained a chronic course. A higher remission rate was observed with ADA (67.4% vs 42.8% with IFX; p = 0.025). Ocular complications decreased from 0.47 to 0.32 per subject. Five patients experienced resolution of structural complications. No patient reported serious AE; 8 (8.8%) experienced 11 minor AE (9 with IFX, 2 with ADA). Conclusion. IFX and ADA appear to be effective and safe for treatment of refractory JIA-related uveitis, with a better performance of ADA in the medium-term period. The Journal of Rheumatology

Original languageEnglish
Pages (from-to)74-79
Number of pages6
JournalJournal of Rheumatology
Volume40
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Juvenile Arthritis
Uveitis
Registries
Safety
Anterior Uveitis
Infliximab
Adalimumab
Rheumatology
Therapeutics
Immunosuppressive Agents
Drug-Related Side Effects and Adverse Reactions
Adrenal Cortex Hormones
Tumor Necrosis Factor-alpha

Keywords

  • Anti-tumor necrosis factor agents
  • Juvenile idiopathic arthritis
  • Treatment
  • Uveitis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis : 1-year followup data from the Italian Registry. / Zannin, Maria E.; Birolo, Carolina; Gerloni, Valeria M.; Miserocchi, Elisabetta; Pontikaki, Irene; Paroli, Maria P.; Bracaglia, Claudia; Shardlow, Alison; Parentin, Fulvio; Cimaz, Rolando; Simonini, Gabriele; Falcini, Fernanda; Corona, Fabrizia; Viola, Stefania; De Marco, Riccardo; Breda, Luciana; La Torre, Francesco; Vittadello, Fabio; Martini, Giorgia; Zulian, Francesco.

In: Journal of Rheumatology, Vol. 40, No. 1, 01.2013, p. 74-79.

Research output: Contribution to journalArticle

Zannin, ME, Birolo, C, Gerloni, VM, Miserocchi, E, Pontikaki, I, Paroli, MP, Bracaglia, C, Shardlow, A, Parentin, F, Cimaz, R, Simonini, G, Falcini, F, Corona, F, Viola, S, De Marco, R, Breda, L, La Torre, F, Vittadello, F, Martini, G & Zulian, F 2013, 'Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry', Journal of Rheumatology, vol. 40, no. 1, pp. 74-79. https://doi.org/10.3899/jrheum.120583
Zannin, Maria E. ; Birolo, Carolina ; Gerloni, Valeria M. ; Miserocchi, Elisabetta ; Pontikaki, Irene ; Paroli, Maria P. ; Bracaglia, Claudia ; Shardlow, Alison ; Parentin, Fulvio ; Cimaz, Rolando ; Simonini, Gabriele ; Falcini, Fernanda ; Corona, Fabrizia ; Viola, Stefania ; De Marco, Riccardo ; Breda, Luciana ; La Torre, Francesco ; Vittadello, Fabio ; Martini, Giorgia ; Zulian, Francesco. / Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis : 1-year followup data from the Italian Registry. In: Journal of Rheumatology. 2013 ; Vol. 40, No. 1. pp. 74-79.
@article{4d641b4c77a24ef3b703f55a5773b146,
title = "Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry",
abstract = "Objective. To evaluate safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of juvenile idiopathic arthritis-related anterior uveitis (JIA-AU). Methods. Starting January 2007, patients with JIA-AU treated with IFX and ADA were managed by a standard protocol and data were entered into the National Italian Registry (NIR). At baseline, all patients were refractory to standard immunosuppressive treatment and/or were corticosteroid-dependent. Data recorded every 3 months included uveitis course, number/type of ocular complications, drug-related adverse events (AE), treatment change or withdrawal, and laboratory measures. Data of patients treated for at least 1 year were retrieved from the NIR and analyzed using descriptive statistics. Treatment efficacy was based on change in uveitis course and in number of ocular complications. Results. Up to December 2009, data for 108 patients with JIA-AU treated with anti-tumor necrosis factor-α agents were recorded in the NIR and data from 91, with at least 12 months' followup, were included in the study. Forty-eight patients were treated with IFX, 43 with ADA. Forty-seven patients (55.3{\%}) achieved remission of AU, 28 (32.9{\%}) had recurrent AU, and 10 (11.8{\%}) maintained a chronic course. A higher remission rate was observed with ADA (67.4{\%} vs 42.8{\%} with IFX; p = 0.025). Ocular complications decreased from 0.47 to 0.32 per subject. Five patients experienced resolution of structural complications. No patient reported serious AE; 8 (8.8{\%}) experienced 11 minor AE (9 with IFX, 2 with ADA). Conclusion. IFX and ADA appear to be effective and safe for treatment of refractory JIA-related uveitis, with a better performance of ADA in the medium-term period. The Journal of Rheumatology",
keywords = "Anti-tumor necrosis factor agents, Juvenile idiopathic arthritis, Treatment, Uveitis",
author = "Zannin, {Maria E.} and Carolina Birolo and Gerloni, {Valeria M.} and Elisabetta Miserocchi and Irene Pontikaki and Paroli, {Maria P.} and Claudia Bracaglia and Alison Shardlow and Fulvio Parentin and Rolando Cimaz and Gabriele Simonini and Fernanda Falcini and Fabrizia Corona and Stefania Viola and {De Marco}, Riccardo and Luciana Breda and {La Torre}, Francesco and Fabio Vittadello and Giorgia Martini and Francesco Zulian",
year = "2013",
month = "1",
doi = "10.3899/jrheum.120583",
language = "English",
volume = "40",
pages = "74--79",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "1",

}

TY - JOUR

T1 - Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis

T2 - 1-year followup data from the Italian Registry

AU - Zannin, Maria E.

AU - Birolo, Carolina

AU - Gerloni, Valeria M.

AU - Miserocchi, Elisabetta

AU - Pontikaki, Irene

AU - Paroli, Maria P.

AU - Bracaglia, Claudia

AU - Shardlow, Alison

AU - Parentin, Fulvio

AU - Cimaz, Rolando

AU - Simonini, Gabriele

AU - Falcini, Fernanda

AU - Corona, Fabrizia

AU - Viola, Stefania

AU - De Marco, Riccardo

AU - Breda, Luciana

AU - La Torre, Francesco

AU - Vittadello, Fabio

AU - Martini, Giorgia

AU - Zulian, Francesco

PY - 2013/1

Y1 - 2013/1

N2 - Objective. To evaluate safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of juvenile idiopathic arthritis-related anterior uveitis (JIA-AU). Methods. Starting January 2007, patients with JIA-AU treated with IFX and ADA were managed by a standard protocol and data were entered into the National Italian Registry (NIR). At baseline, all patients were refractory to standard immunosuppressive treatment and/or were corticosteroid-dependent. Data recorded every 3 months included uveitis course, number/type of ocular complications, drug-related adverse events (AE), treatment change or withdrawal, and laboratory measures. Data of patients treated for at least 1 year were retrieved from the NIR and analyzed using descriptive statistics. Treatment efficacy was based on change in uveitis course and in number of ocular complications. Results. Up to December 2009, data for 108 patients with JIA-AU treated with anti-tumor necrosis factor-α agents were recorded in the NIR and data from 91, with at least 12 months' followup, were included in the study. Forty-eight patients were treated with IFX, 43 with ADA. Forty-seven patients (55.3%) achieved remission of AU, 28 (32.9%) had recurrent AU, and 10 (11.8%) maintained a chronic course. A higher remission rate was observed with ADA (67.4% vs 42.8% with IFX; p = 0.025). Ocular complications decreased from 0.47 to 0.32 per subject. Five patients experienced resolution of structural complications. No patient reported serious AE; 8 (8.8%) experienced 11 minor AE (9 with IFX, 2 with ADA). Conclusion. IFX and ADA appear to be effective and safe for treatment of refractory JIA-related uveitis, with a better performance of ADA in the medium-term period. The Journal of Rheumatology

AB - Objective. To evaluate safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of juvenile idiopathic arthritis-related anterior uveitis (JIA-AU). Methods. Starting January 2007, patients with JIA-AU treated with IFX and ADA were managed by a standard protocol and data were entered into the National Italian Registry (NIR). At baseline, all patients were refractory to standard immunosuppressive treatment and/or were corticosteroid-dependent. Data recorded every 3 months included uveitis course, number/type of ocular complications, drug-related adverse events (AE), treatment change or withdrawal, and laboratory measures. Data of patients treated for at least 1 year were retrieved from the NIR and analyzed using descriptive statistics. Treatment efficacy was based on change in uveitis course and in number of ocular complications. Results. Up to December 2009, data for 108 patients with JIA-AU treated with anti-tumor necrosis factor-α agents were recorded in the NIR and data from 91, with at least 12 months' followup, were included in the study. Forty-eight patients were treated with IFX, 43 with ADA. Forty-seven patients (55.3%) achieved remission of AU, 28 (32.9%) had recurrent AU, and 10 (11.8%) maintained a chronic course. A higher remission rate was observed with ADA (67.4% vs 42.8% with IFX; p = 0.025). Ocular complications decreased from 0.47 to 0.32 per subject. Five patients experienced resolution of structural complications. No patient reported serious AE; 8 (8.8%) experienced 11 minor AE (9 with IFX, 2 with ADA). Conclusion. IFX and ADA appear to be effective and safe for treatment of refractory JIA-related uveitis, with a better performance of ADA in the medium-term period. The Journal of Rheumatology

KW - Anti-tumor necrosis factor agents

KW - Juvenile idiopathic arthritis

KW - Treatment

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=84871873566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871873566&partnerID=8YFLogxK

U2 - 10.3899/jrheum.120583

DO - 10.3899/jrheum.120583

M3 - Article

C2 - 23118110

AN - SCOPUS:84871873566

VL - 40

SP - 74

EP - 79

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 1

ER -